Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults.

IF 1.1 4区医学 Q3 OTORHINOLARYNGOLOGY

Journal of Laryngology and Otology Pub Date : 2024-12-01 Epub Date: 2024-10-21 DOI:10.1017/S0022215124001026

Edward Balai, Emilie Ac Dronkers, Chadwan A Yaghchi, Dorothy Gujral, Guri Sandhu, Aphrodite Iacovidou

{"title":"Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults.","authors":"Edward Balai, Emilie Ac Dronkers, Chadwan A Yaghchi, Dorothy Gujral, Guri Sandhu, Aphrodite Iacovidou","doi":"10.1017/S0022215124001026","DOIUrl":null,"url":null,"abstract":"Objective: Recurrent respiratory papillomatosis is a rare disease characterised by growth of papilloma within the respiratory tract. The disease course is variable but can require frequent surgical interventions alongside adjuvant medical treatments. There is no definitive curative treatment or gold-standard guidelines for management. We aimed to evaluate current and potential future adjuvant treatments and propose a management guideline for adult patients.Methods: Relevant articles were identified through searching databases, reference lists and grey literature.Results: Systemic bevacizumab appears to be the most effective adjuvant treatment currently available. However, intralesional cidofovir also achieves a high complete-response rate in adults and the Gardasil vaccine demonstrates preventative and therapeutic value. The INO-3107 DNA vaccine is a promising potential future adjuvant treatment.Conclusions: This review provides a detailed examination of current and potential future adjuvant treatments. Based on the literature, we have developed a management guideline for adult patients with recurrent respiratory papillomatosis.","PeriodicalId":16293,"journal":{"name":"Journal of Laryngology and Otology","volume":" ","pages":"1133-1143"},"PeriodicalIF":1.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laryngology and Otology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0022215124001026","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Recurrent respiratory papillomatosis is a rare disease characterised by growth of papilloma within the respiratory tract. The disease course is variable but can require frequent surgical interventions alongside adjuvant medical treatments. There is no definitive curative treatment or gold-standard guidelines for management. We aimed to evaluate current and potential future adjuvant treatments and propose a management guideline for adult patients.

Methods: Relevant articles were identified through searching databases, reference lists and grey literature.

Results: Systemic bevacizumab appears to be the most effective adjuvant treatment currently available. However, intralesional cidofovir also achieves a high complete-response rate in adults and the Gardasil vaccine demonstrates preventative and therapeutic value. The INO-3107 DNA vaccine is a promising potential future adjuvant treatment.

Conclusions: This review provides a detailed examination of current and potential future adjuvant treatments. Based on the literature, we have developed a management guideline for adult patients with recurrent respiratory papillomatosis.

查看原文本刊更多论文

复发性呼吸道乳头状瘤病的辅助治疗：描述性综述和成人管理指南建议。

目的：复发性呼吸道乳头状瘤病是一种以呼吸道内乳头状瘤生长为特征的罕见疾病。病程是可变的，但可能需要频繁的手术干预和辅助药物治疗。目前还没有确定的治疗方法或黄金标准的管理指南。我们旨在评估当前和潜在的未来辅助治疗，并提出成人患者的管理指南。方法：通过检索数据库、参考文献表、灰色文献等方法对相关文献进行筛选。结果：全身贝伐单抗似乎是目前可用的最有效的辅助治疗。然而，病变内西多福韦在成人中也达到了很高的完全缓解率，加德西疫苗显示出预防和治疗价值。INO-3107 DNA疫苗是一种很有前途的未来辅助治疗方法。结论：本综述提供了当前和潜在的未来辅助治疗的详细检查。在文献的基础上，我们制定了成人复发性呼吸道乳头状瘤病的治疗指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Laryngology and Otology 医学-耳鼻喉科学

CiteScore

3.20

自引率

11.80%

发文量

593

审稿时长

3-6 weeks

期刊介绍： The Journal of Laryngology & Otology (JLO) is a leading, monthly journal containing original scientific articles and clinical records in otology, rhinology, laryngology and related specialties. Founded in 1887, JLO is absorbing reading for ENT specialists and trainees. The journal has an international outlook with contributions from around the world, relevant to all specialists in this area regardless of the country in which they practise. JLO contains main articles (original, review and historical), case reports and short reports as well as radiology, pathology or oncology in focus, a selection of abstracts, book reviews, letters to the editor, general notes and calendar, operative surgery techniques, and occasional supplements. It is fully illustrated and has become a definitive reference source in this fast-moving subject area. Published monthly an annual subscription is excellent value for money. Included in the subscription is access to the JLO interactive web site with searchable abstract database of the journal archive back to 1887.